Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Pliant Therapeutics to similar companies based on the strength of its institutional ownership, valuation, earnings, analyst recommendations, dividends, profitability and risk.
Valuation & Earnings
This table compares Pliant Therapeutics and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Pliant Therapeutics | $1.58 million | -$149.34 million | -0.41 |
| Pliant Therapeutics Competitors | $704.12 million | $8.07 million | -17.98 |
Pliant Therapeutics’ peers have higher revenue and earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Institutional and Insider Ownership
97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 8.7% of Pliant Therapeutics shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Pliant Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pliant Therapeutics | N/A | -57.13% | -44.97% |
| Pliant Therapeutics Competitors | -12,519.20% | -215.47% | -31.42% |
Analyst Ratings
This is a summary of recent ratings for Pliant Therapeutics and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pliant Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Pliant Therapeutics Competitors | 9959 | 15361 | 45766 | 1602 | 2.54 |
Pliant Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 404.12%. As a group, “Biotechnology” companies have a potential upside of 114.69%. Given Pliant Therapeutics’ higher probable upside, equities analysts plainly believe Pliant Therapeutics is more favorable than its peers.
Summary
Pliant Therapeutics peers beat Pliant Therapeutics on 7 of the 13 factors compared.
Pliant Therapeutics Company Profile
Pliant Therapeutics is a biopharmaceutical company focused on developing medicines for fibrotic diseases, in which excess scar tissue can impair the function of organs. The company’s research centers on integrins, proteins involved in processes such as tissue repair and fibrosis. Its investigational programs have included bexotegrast, an oral drug designed to inhibit the αvβ6 and αvβ1 integrins and studied for conditions including idiopathic pulmonary fibrosis. Pliant has also pursued other drug candidates targeting fibrotic disease pathways.
Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
